ERBB2 and breast carcinoma: Ribociclib combined with AI is the first-line therapy in HR-positive, HER2-negative advanced breast cancer since the data published in MONALEESA-2 and MONALEESA-7 trials show substantial benefit in progression-free survival (PFS) and overall survival (OS) compared with hormonal therapy alone.